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ABSTRACT 
 
Objectives  
To report the distribution of intraocular pressure (IOP) by age and sex, and the frequency of 
glaucoma in the EPIC-Norfolk cohort.  
 
Desig  
A community-based cross-sectional observational study. 
 
Setting  
The city of Norwich and the surrounding rural and urban areas.  
  
Participants 
8623 participants aged 48-92 years recruited from the community who underwent ocular 
examination to identify glaucoma. 
 
Main outcome measures 
The frequency and characteristics of glaucoma in the cohort, IOP distribution, and the 
sensitivity and specificity of IOP in diagnosing glaucoma.  
 
Results  
A total of 363 participants (4.2%) had glaucoma in either eye, 86.5% of whom had primary 
open angle glaucoma (POAG). 607 subjects (7.0%) were glaucoma suspects, and 863 
(10.0%) were ocular hypertensives. 66.6% of glaucoma cases had been previously 
diagnosed. The cohort’s mean IOP was 16.3mmHg (95% CI 16.2-16.3mmHg, SD 
3.6mmHg), and 65% of POAG cases had IOP less than the ocular hypertension threshold of 
21mmHg. No one IOP level provided adequately high sensitivity and specificity for glaucoma 
diagnosis.  
 
Conclusions   
In this British community, glaucoma, suspected glaucoma and ocular hypertensio  represent 
a large number of potential referrals to the hospital eye service. The use of IOP for 
glaucoma case-finding is probably not viable.  
 
 
 
Page 2 of 19
https://mc.manuscriptcentral.com/bmj
BMJ
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 3
INTRODUCTION  
 
Glaucoma is the leading cause of irreversible blindness in the world1 and the second most 
common cause of registered blindness in England and Wales.2 It comprises a group of 
ocular diseases of progressive damage of the optic nerve, with characteristic structural optic 
disc changes and visual field defects.3 Glaucoma and suspect glaucoma combined account 
for the sixth largest share of NHS outpatient attendances in England, after general medical 
examination, breast cancer, schizophrenia, prostate cancer and joint pain. 4 The most 
common type of glaucoma among white populations is primary open angle glaucoma 
(POAG); primary angle closure glaucoma (PACG), which results from occlusion of aqueous 
humour outflow, is more common among Asians;5 secondary glaucoma results from a 
diverse range of ocular and systemic conditions. Elevated intraocular pressure (IOP) is the 
major modifiable risk factor for POAG, 6 7 8 but around 50% of glaucoma cases present with 
IOP below 21mmHg, the threshold defined as ocular hypertension, which was raised IOP 
without any evidence of glaucoma. 9 The EPIC-Norfolk Eye Study, initiated in 2004, is the 
most recent large-scale eye survey in the UK. The aim of this study was to report  the 
frequency and characteristics of glaucoma and IOP distribution of the study participants.  
 
METHODS 
The European Prospective Investigation of Cancer (EPIC) study is a pan-European multi-
cohort study, designed to investigate the lifestyle determinants of cancer risks. The EPIC-
Norfolk cohort was established in the city of Norwich and the surrounding rural and urban 
areas, in the eastern English county of Norfolk, between 1993-1997.10 A total of 30,445 men 
and women aged 40-79 years were recruited at a baseline survey from the databases of 35 
general practices. The predominant ethnicity of the cohort was white, and included 
individuals across the range of socioeconomic status and educational achievements. The 
EPIC-Norfolk Eye study was carried out between 2004-2011 when ophthalmic data were 
collected from 8,623 participants.11 The work was carried out with the approval of the East 
Norfolk & Waverney NHS Research Governance Committee (2005EC07L) and the Norfolk 
Research Ethics Committee (05/Q0101/191), in accordance with the principles of the 
Declaration of Helsinki.  
The first 443 sequential participants had IOP measured with a non-contact tonometer 
(AT555, Reichert Corporation, Philadelphia, USA), and the remaining participants had three 
IOP measurements for each eye made with the Ocular Response Analyzer non-contact 
analyzer  (ORA; Reichert Corporation, Philadelphia, USA) using software version 3.01. The 
ORA flattens the cornea with a jet of air and uses an electro-optical system to measure the 
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air pressures at which the cornea flattens both inwards and outwards. The average of the 
two ORA pressure values are calibrated linearly against the Goldmann applanation 
tonometer (GAT) to provide a Goldmann-equivalent IOP measurement (IOPg, mmHg).12  
A systematic review showed that among 12 studies that directly compared the agreement of 
IOPg and GAT, the mean difference between the two (IOPg-GAT) is 1.5mmHg (95% 
predictived interval -0.6 to 3.7mmHg). 13 
The glaucoma status of the subjects was determined from the systematic examination of all 
subjects, which included visual acuity, tonometry, optic nerve head assessment (Heidelberg 
Retina Tomograph II) and peripapillary nerve fibre layer assessment with scanning laser 
polarimetry (GDx VCC, Zeiss, Dublin, California, USA). A 24-2 central threshold visual field 
test (Humphrey 750i Visual Field Analyzer, Carl Zeiss Meditech Ltd, Welwyn Garden City, 
UK) was performed in those participants with abnormal findings on HRT or GDx-VCC, and in 
1 out of 10 subjects with normal findings. Subjects with abnormal findings who met a set of 
predefined criteria designed to detect glaucoma were referred to the Eye Department of the 
Norfolk & Norwich University Hospital for a definitive eye examination by a consultant 
ophthalmologist with a specialist interest in glaucoma (DCB). A detailed description of the 
study design has been published previously.11 Glaucoma was defined as the presence of 
characteristic structural optic disc abnormalities and visual field loss, with no other 
explanations for the disc and field appearances. The differentiation of high tension and 
normal tension glaucoma was based on IOP level before glaucoma treatment commenced. 
Glaucoma suspect was defined as the presence of early or minor glaucomatous disc 
features, associated with a normal visual field or the absence of visual field data.  Ocular 
hypertension was defined as IOP>21mmHg with no features of glaucoma in the optic disc or 
visual field. Specific quantitative methods and principles for diagnosis of POAG and 
suspected POAG observed the International Society of Geographical and Epidemiological 
Ophthalmology (ISGEO) diagnostic principles.3 A further refinement process was in place to 
limit false positives or false negatives by reviewing all examination findings and history of a 
high-risk subset of subjects by another consultant glaucoma ophthalmologist (PJF). A 
summary diagram for the flow of participants through the study and the glaucoma diagnostic 
process is in Appendix I. Glaucoma diagnosis per person was determined by taking the 
clinically more serious diagnosis of either eye, in the following hierarchy (most serious to 
least serious): glaucoma, glaucoma suspect, ocular hypertension (IOP>21mmHg), narrow 
angle spectrum (primary angle closure, primary angle closure suspect and narrow angles), 
and normal.  
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Statistical Analysis 
IOP reported for the cohort was the mean of left and right eyes’ mean IOP, using the ORA 
IOPg or the AT555 NCT values. Sensitivities and specificities of IOP for glaucoma detection 
in Figure 4 and Table 6 were derived from the ability of various IOP thresholds to 
differentiate between subjects with all cause glaucoma in either eye, and subjects with no 
glaucoma in either eye. The reporting of this study conformed to the STROBE statement.14  
All statistical analyses were performed using STATA (Stata/SE 13.1, StataCorp, College 
Station, Texas). 
 
RESULTS 
There were 8,623 participants in the EPIC-Norfolk Eye Study, their mean age was 68.7 
years (range 48-92 years), and 55% were female. Compared to the population estimates for 
Norfolk and for the UK, the study population was older, and had a decreasing proportion of 
women with age, which is opposite to the Norfolk and UK population’s trend of an increasing 
proportion of women with age (Figure 1). The study population comprised of 99.4% 
Caucasians, while Norfolk and the UK had 96.5% and 87.2% Caucasians respectively.15  
 
Table 1 and 2 show the glaucoma diagnosis by eye and by person. A total of 363 
participants (4.2%, 95% CI 3.8-4.6%) had glaucoma in either eye, 315 had POAG (3.6% 
(95% CI 3.3-4.0%), 607 (7.0%) were glaucoma suspects, 863 (10.0%) were ocular 
hypertensives (untreated IOP>21mmHg), 54 (0.6%) had narrow angle spectrum. Twenty-
three participants (0.3%) had no recorded diagnosis, as they declined or were unable to 
undergo definitive eye examination after failing the screening tests. The majority of people 
with glaucoma had POAG (86.5%), with an equal proportion of high pressure and normal 
pressure glaucoma. Out of the 523 glaucoma eyes, formal visual field assessment was not 
feasible in 28 due to poor vision. Most of these participants had secondary glaucoma which 
was diagnosed by advanced disc cupping and uncontrolled IOP.  
 
Among the glaucoma cases, 242 (66.6%) were previously known, and 66.3% of POAG 
cases were previously known. The glaucoma prevalence in the study population increased 
with age, and was higher among men than women (Table 4).  
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Table 1. Glaucoma diagnosis per eye  
  Right eye   Left eye  
Glaucoma diagnosis  n %  n % 
Normal  7091 82.2  7061 81.9 
Primary open angle glaucoma 
       High tension glaucoma 
       Normal tension glaucoma 
 236 
121 
115 
2.7 
        1.4 
        1.3 
 231 
        121 
        109 
2.7 
      1.4 
      1.3 
Primary angle closure glaucoma  20 0.2  17 0.2 
Secondary glaucoma  9 0.1  11 0.1 
Subtotal with glaucoma  265 3.1  258 3.0 
Suspect OAG  444 5.2  443 5.1 
OHT & Suspect OAG  67 0.8  67 0.8 
Suspect ACG  27 0.3  28 0.3 
Secondary OHT / OAG suspect  2 0.0  4 0.1 
Subtotal glaucoma suspects  540 6.3  542 6.3 
OHT  641 7.4  670 7.8 
PAC  27 0.3  32 0.4 
Narrow angles  36 0.4  34 0.4 
Not recorded  23 0.3  26 0.3 
Total   8623 100  8623 100 
OAG open angle glaucoma; ACG angel closure glaucoma; OHT ocular hypertension; PAC primary 
angle closure 
 
Table 2.  Glaucoma diagnosis per person  
Diagnosis n % 
Normal 6,713 77.9 
Glaucoma 363 4.2 
Glaucoma suspect 607 7.0 
Ocular hypertension 863 10.0 
Narrow angle spectrum 54 0.6 
Unrecorded 23 0.3 
Total 8623 100 
* More serious diagnosis of either eye used, in the following hierarchy (most serious to least serious) - 
glaucoma, glaucoma suspect, ocular hypertension, narrow angles spectrum (primary angle closure, 
primary angle closure suspect), normal, diagnosis not recorded 
 
Table 3. Glaucoma type per person  
Diagnosis  n 
 
% 
Primary open angle glaucoma 
             High tension glaucoma 
             Normal tension glaucoma 
314 
          157 
          157 
86.5 
     43.3 
     43.3 
Primary angle closure glaucoma 29  8.0 
Secondary glaucoma 20  5.5 
                                                Total (all glaucoma)  363 100 
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Table 4. Glaucoma per person by age and sex  
 All Cause glaucoma Primary open angle glaucoma 
 Men Women Men Women 
Age (yrs) n % of age 
group 
n % of age 
group 
n % of age 
group 
n % of age 
group 
<55 1 0.8 1 0.5 1 0.8 1 0.5 
55-60 4 1.5 5 1.0 4 1.5 5 1.0 
60-65 20 2.3 19 1.5 16 1.8 15 1.2 
65-70 34 4.3 22 2.2 27 3.4 21 2.1 
70-75 50 6.6 42 5.0 44 5.8 31 3.7 
75-80 43 7.2 30 4.9 39 6.6 26 4.3 
80+ 48 11.2 44 10.8 44 10.5 41 10.1 
Total  200 5.2 163 3.4 175 4.5 140 3.0 
 
8,401 subjects had IOP measured (7,958 with ORA, 443 with AT555 NCT), 243 of them 
used ocular hypotensive eyedrops in either eye.  Figure 2 shows the distribution of mean 
IOP of both eyes, which followed an approximately Gaussian distribution, with a right skew 
and an exaggerated peak. The cohort mean IOP was 16.3mmHg (95%CI 16.2-16.3mmHg, 
SD 3.6mmHg). Table 5 shows the cohort’s IOP distribution by age and sex. The mean IOP 
for glaucomatous eyes was 16.7mmHg (95%CI 17.1-18.1mmHg, range 4.0-45.6mHg), and 
the percentage of eyes with glaucoma increases with IOP (Figure 3).  
 
Table 6 and figure 4 show the sensitivity and specificity of glaucoma detection at different 
IOP thresholds. Overall, sensitivity for glaucoma detection was poor at all IOP levels shown, 
regardless of the additional refining parameters of age and sex, and there was no one single 
IOP level that afforded both high sensitivity and specificity. 
 
Table 5. Intraocular pressure* distribution by age and sex in the EPIC-Norfolk cohort 
Age groups (yrs) Males Females 
 n 
IOP mmHg 
mean (95% CI ) n 
IOP mmHg 
mean (95% CI) 
<55 128 15.9 (15.4-16.5) 185 15.7 (15.2-16.2) 
55 to <60 262 15.8 (15.4-16.3) 473 15.9 (15.6-16.2) 
60 to <65 857 16.4 (16.2-16.7) 1240 16.5 (16.3-16.6) 
65 to <70 790 16.2 (15.9-16.4) 969 16.7 (16.5-17.0) 
70 to <75 746 16.3 (16.0-16.5) 808 16.3 (16.1-16.6) 
75 to <80 570 16.0 (15.7-16.4) 591 16.2 (15.9-16.4) 
≥80 402 16.0 (15.6-16.4) 380 15.8 (15.5-16.2) 
                          Total  3755 16.2 (16.1-16.3) 4646 16.3 (16.2-16.4) 
*Mean IOP of both eyes
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Table 6. All cause glaucoma- sensitivity and specificity of detection at different intraocular pressure thresholds  
IOP 
mmHg 
Sensitivity (%) Specificity (%) 
 
Overall 
Age 
Male Female  Overall 
Age 
Male Female  
<65 ≥65 <70 ≥70 <65 ≥65 <70 ≥70 
>19 45.0 36.7 46.3 45.6 44.7 49.2 39.7 73.2 74.1 72.6 72.8 73.6 73.7 72.7 
>20 36.3 26.5 37.9 34.0 37.3 42.4 28.9 81.0 82.0 80.3 80.9 81.0 80.5 81.3 
>21 30.0 24.5 30.9 28.2 30.7 35.1 23.7 86.9 87.7 86.4 86.8 87.0 85.8 87.7 
>22 25.4 22.5 25.8 23.3 26.2 30.4 19.2 91.2 91.9 90.7 91.1 91.3 90.3 91.9 
>23 20.5 18.4 20.8 20.4 20.5 24.6 15.4 94.0 94.5 93.8 93.8 94.5 93.2 94.7 
>24 16.7 18.4 16.4 16.5 16.8 20.9 11.5 96.0 96.2 95.9 95.7 96.4 95.4 96.5 
>25 12.1 12.2 12.1 10.7 12.7 16.2 7.1 97.1 97.0 97.2 96.9 97.5 96.6 97.6 
>26 7.8 8.2 7.7 6.8 8.2 11.0 3.9 98.0 97.8 98.1 97.8 98.3 97.5 98.4 
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DISCUSSION  
 
Glaucoma prevalence data have been reported from populations in the US, 16 17 Australia, 18 
19 Europe 20-22 and South East Asia 23-26. However, recent data from the UK is lacking, with 
the last published cross-sectional population glaucoma surveys were one from a rural West 
of Ireland in 1993 27, and another from north London in 1998. 28  
There are differences between the EPIC-Norfolk participants and the local population of 
Norfolk, as the study participants were not sampled systematically, but recruited by inviting 
all adults aged >40 years from GP practices. Apart from differences in age and sex 
composition, EPIC-Norfolk participants were less likely to live in deprived areas and were 
potentially healthier due to the volunteer nature of the study. The glaucoma cases derived in 
the cohort therefore may not be fully representative of the local or national population and 
are likely an underestimation of the true numbers. Nevertheless, results in this study 
corroborated many established trends in glaucoma epidemiology. Our predominant 
glaucoma type was POAG, a consistent finding among European populations.5 29 The 
prevalence of POAG in this cohort increased with age, which is its strongest known risk 
factor.30 The frequency of all cause glaucoma in the cohort, aged 48 to 92 years, was 4.2% 
(95%CI 3.8-4.6%), and 3.7% (95%CI 3.3-4.0%) for POAG. This echoed findings from a 
meta-analysis in 2014, whereby the prevalence of glaucoma (POAG and PACG) for 
Europeans aged 40-80 years was 2.93% (95%CI 1.85-4.40%), and the prevalence of POAG 
was 2.51% (95% CI 1.54-3.89%).5 In another meta-analysis published in 2006, the pooled 
prevalence of POAG for white population was of 2.1% (95%CI 1.6-2.7%).31 
We found 66% of POAG cases in the cohort to be previously diagnosed. This is the highest 
reported figure from a major community-based study. Previous reported figures include 49% 
in the Blue Mountains Eye Study, 18 40% in Melbourne’s Visual Impairment Study, 50% in 
the Thessaloniki Eye Study,22 47% in the Rotterdam Eye Study,20  and 50% among the white 
subjects in the Baltimore Eye Survey.32  Glaucoma is a largely asymptomatic disease with 
insiduous onset. In most industrialised countries, it is detected by opportunistic case finding, 
and relies on people being examined by an eye care professional. In the UK, this would 
usually be a community optometrist. Suspected glaucoma cases are then referred to 
ophthalmologists for definitive diagnosis and management. The higher rate of previously 
known glaucoma cases in EPIC-Norfolk than other studies could reflect either better health 
care access among the study participants due to recruitment bias, or generally more 
effective health care provision in the UK with universal access and free eye tests for those 
over 60 years old in the National Health Service (NHS).  
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A striking finding in the study was the large number of glaucoma suspects (7%) and ocular 
hypertensives (10%). Collectively they represent a large number of potential referrals to the 
Hospital Eye Services (HES), many of whom remain under observation for up to 5 years.33  
This is reflected by the existing burden to the HES, whereby ocular hypertension accounts 
for 30-45% of the referrals it receives.34 35  Coupled with the fact that glaucoma is a chronic 
disease that needs regular and long-term follow-up, it is no wonder that glaucoma and 
suspected glaucoma account for the sixth largest share of NHS outpatient attendances.4 
While raised IOP is the strongest risk factor for POAG after age,30 our data reiterate that no 
single IOP level provides sufficiently high sensitivity and specificity for glaucoma case 
detection, as shown in Figure 3, mirroring results from the Baltimore Eye Survey.16 This 
reinforces the principle that IOP alone without optic disc examination or visual field test is not 
an effective screening tool for glaucoma.  
 
There were several sources of under-reporting of glaucoma diagnosis in this study. Only 
18% of study subjects underwent visual field testing. Lack of routine field testing in a 
population study had been shown in a meta-analysis as a study design factor that led to 
under-diagnosis.36 However, in our study, both disc and field abnormalities were re-
requisites of a glaucoma diagnosis, observing well-established diagnostic principles used in 
most population cross sectional studies.17 20 23 32 37 38 We used a multimodal optic disc 
examination to uncover glaucomatous damage and determine who was referred for a 
definitive exam. We therefore expect very few cases of glaucoma would have been missed. 
The number of narrow angle cases is also likely to be underestimated, as gonioscopy or 
anterior chamber depth assessment on slitlamp were not part of the screening test, although 
those with PACG should not have been missed because of that, as all glaucoma suspects 
underwent a full examination.  
 
WHAT IS KNOWN ABOUT THIS TOPIC  
Glaucoma is the leading cause of irreversible blindness in the world and the second most 
common cause of registered blindness in England and Wales. The management of 
glaucoma, glaucoma suspects and ocular hypertensives accounts for a significant amount of 
NHS outpatient resources. While the prevalence of glaucoma has been reported in many 
population studies worldwide, there are no recent data for glaucoma in the UK.  
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WHAT THIS PAPER ADDS  
This study provides the most current data on frequency and type of glaucoma in a British 
community. We identified a large number of ocular hypertensives and glaucoma suspects. 
These figures provide useful information for service planning. The large number of glaucoma 
subjects with IOP less than 21mmHg reinforces the weakness of relying on IOP in glaucoma 
case detection.  
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Figure 1 Age and sex distribution of the EPIC-Norfolk 3HC cohort compared to the 
population of Norfolk & the UK (Source: 2014 mid-year population estimates in the UK, 
Office for National Statistics) 15 
 
 
 
 
 
 
 
 
 
 
 
0 
5 
10 
15 
20 
25 
30 
45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 ≥85 
% age ≥45 
Age group (years) 
EPIC-Norfolk 3HC cohort (n=8623) 
Norfolk popula on age≥45 (n=439,300) 
UK popula on age≥45 (n=27,891,767) 
40 
45 
50 
55 
60 
65 
70 
45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 ≥85 
% women  
Age group (years) 
EPIC-Norfolk 3HC cohort (n=8623) 
Norfolk popula on age≥45 (n=439,300) 
UK popula on age≥45 (n=27,891,767) 
Page 16 of 19
https://mc.manuscriptcentral.com/bmj
BMJ
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
 17 
Figure 2.  Distribution of IOP in the EPIC-Norfolk population (n=8401) 
The distribution approximates a Gaussian distribution, but has an exaggerated central peak 
and a modest right skew. 
 
 
Figure 3. Intraocular pressure for all eyes and eyes with glaucoma in the EPIC-Norfolk 
cohort  
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Figure 4. Sensitivity and specifity for all cause glaucoma detection in the EPIC-Norfolk 
cohort 
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Appendix I: Flow of participants through the EPIC-Norfolk Eye Study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Participants meeting referral criteria (n=1770) Participants not meeting referral criteria (n=6853) 
Final glaucoma diagnosis 
 
Definitive Examination at NNUH Eye Department   
Full ocular examination, including gonioscopy & 
central corneal thickness.  Automated perimetry 
performed if deemed clinically indicated.  
Diagnosis refinement process  
Diagnosis verified by consultant 
ophthalmologist based on history, disc photos 
& perimetry results 
A subset of subjects with any of 
the following:  
Visual field test “outside normal 
limits”  
CDR >0.6 either eye 
CDR asymmetry >0.3 
 
Screening tests (n=8623) 
•               LogMAR visual acuity 
•          Intraocular pressure tonometry (Reichert’s Ocular Response Analyzer) (n=7958) 
 or            NCT-533 Intraocular pressure (n=443) 
•               Ocular biometry (IOLMaster) (n=8033) 
•               Scanning laser polarimetry (GDx-VCC) (n=7920) 
•               Scanning laser ophthalmoscopy (HRT II)  (n=7861) 
•               Fundus photo (non-mydriatic 30 °single field) (n=7497) 
•          Automated perimetry (n= 1459)  
 
 
EPIC-Norfolk Eye Study 
(n=8623) 
 
Referral criteria based on abnormalities on:  
visual acuity, intraocular pressure, HRT II, Gdx-VCC, or 
manifest abnormalities on funds photos  
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